Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck to Invest €50M in Bari Production Site

Published: Wednesday, May 21, 2014
Last Updated: Wednesday, May 21, 2014
Bookmark and Share
Company to invest €50 million in its Italian production site in respond to the rising demand for biopharmaceuticals.

The announcement was made by Karl-Ludwig Kley, Chairman of the Executive Board of Merck, during a press conference held today at the Bari plant, in the presence of the Italian Prime Minister Matteo Renzi, and of the President of the Italian Pharma Industries Association Farmindustria, Massimo Scaccabarozzi.

Within Merck Serono's global biotech production network, the Bari site is part of fill & finish operations alongside the facilities in Darmstadt and Aubonne (Switzerland). The drugs produced within this global network are seeing long-term growing demand, especially as regards those to treat infertility. The new production facility in Bari, southern Italy, is to be commissioned in 2017 for the sterile filling and packaging of liquid drugs into syringes, vials and ampoules (fill & finish).

"To make Merck fit for the future, we are also investing in modern, expanded production capacities in order to meet the rising demand for our drugs," said Kley, making reference to the "Fit for 2018" transformation and growth program. During his visit to the Bari site today, he explained the reasons for the investment: "This is part of our growth plans for Merck and for the Merck Serono division in particular here in Bari, where we have excellent conditions thanks to highly skilled employees and a very good infrastructure. Patients will also benefit from this investment as we secure the supply of drugs that improve the quality of life of people around the globe."

Merck generates more than half of the sales of its Merck Serono division with biotech products. Among others, the company is the world market leader in the treatment of infertility. Around two million babies of the five million born with the help of infertility drugs worldwide were conceived with the aid of Merck Serono products.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Exploring the Biopharma Industry's Evolving Risk Model
Study highlights biopharma industry's current and future growth drivers.
Wednesday, June 08, 2016
Merck, NewLink Genetics Enter Ebola Vaccine Agreement
Companies have entered an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink’s investigational rVSV-EBOV (Ebola) vaccine candidate.
Wednesday, November 26, 2014
Merck Announces $5 Billion Accelerated Share Repurchase
Merck announced that it has entered into an accelerated share repurchase agreement (ASR) with Goldman, Sachs & Co. to repurchase $5 billion of Merck’s common stock.
Wednesday, May 22, 2013
Fujifilm to Acquire Merck Biomanufacturing Network
FUJIFILM Corporation and Merck announces they have entered into a definitive agreement by which Fujifilm will acquire the Merck BioManufacturing Network.
Thursday, March 03, 2011
Scientific News
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Improved Stability, Shelf Life of Protein Drugs
Study improves protein drug stability and extend their shelf life by tested a novel route for non-covalent protein modification.
More Effective Strategy for Producing Flu Vaccines
Researchers have developed a virus backbone, allowing producers to grow vaccine viruses in mammalian cells, rather than in eggs.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Fighting Off HIV Infection Closer to Reality
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection.
Powerful New Tools to Combat Zika
Researchers have created a way to replicate the stucture of Zika virus, removing the genes that make the virus infectious.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!